A recent study demonstrated that combining MWA with CAR-T cells targeting a receptor tyrosine kinase (AXL) (AXL-CAR T cells) in NSCLC patient-derived xenografts, enhances the infiltration, activation, persistence, and tumor killing [275]. The gene discussed is AXL; the disease is neoplasm.